Symbiotec Pharmalab IPO: Symbiotec Pharmalab Limited is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients and specialty products. The company has come up with its IPO in the market to raise ₹1,757.00 crore. Symbiotec Pharmalab IPO will open for subscription on August 24, 2026, and close August 27, 2026.
Symbiotec Pharmalab IPO is a book build issue of 1,77,86,442 shares (₹1,757.00 Cr.). The issue is a combination of a fresh issue of 15,21,261 shares (₹150.00 Cr.) and an offer for sale of 1,62,65,181 shares (₹1,607.00 Cr.).
The price band for Symbiotec Pharmalab IPO is ₹938 to ₹988 per share. The minimum application size is 1 lot (15 shares), requiring a retail investor to invest at least ₹14,820 (based on the upper price band).
Symbiotec Pharmalab IPO Details
| Open Date | August 24, 2026 |
| Close Date | August 27, 2025 |
| Issue Type | Book Building Issue |
| Face Value | ₹2.00 Equity Share |
| Price Band | ₹938 – ₹988 Per Share |
| Listing On | BSE, NSE |
| Issue Size | ₹1,757.00 Cr. (1,77,86,442 Shares) |
| Fresh Issue | ₹150.00 Cr. (15,21,261 Shares) |
| Offer For Sale | ₹1,607.00 Cr. (1,62,65,181 Shares) |
| Employee Discount | ₹90.00 |
| Prospectus | RHP | Anchor Investors |
Symbiotec Pharmalab IPO Reservation
| Category | Net Issue | Total Issue | Shares Offered |
|---|---|---|---|
| QIB | 50.00% | 49.91% | 88,76,517 |
| NII | 15.00% | 14.97% | 26,62,955 |
| Retail | 35.00% | 34.93% | 62,13,562 |
| Employee Preferential Reservations | — | 0.19% | 33,408 |
| Total | 100.00% | 100.00% | 1,77,86,442 |
Symbiotec Pharmalab IPO Market Lot
| Application | Lot | Shares | Amount |
| Retail Minimum | 1 | 15 | ₹14,820 |
| Retail Maximum | 13 | 195 | ₹1,92,660 |
| S-HNI Minimum | 14 | 210 | ₹2,07,480 |
| S-HNI Maximum | 67 | 1,005 | ₹9,92,940 |
| B- HNI Minimum | 68 | 1,020 | ₹10,07,760 |
Key Performance Indicator
| KPI (March 31, 2026) | Value |
| Market Capitalisation | ₹6,244.43 Cr. (On Upper Price) |
| P/E Ratio | 55.44x |
| EPS | ₹17.82 |
| ROE | 11.19% |
| ROCE | 11.56% |
| RoNW | 9.48% |
| Dept/Equity | — |
| EBITDA Margin | 26.59% |
| PAT Margin | 12.60% |
| Net Assets Value | ₹184.69 |
| Price To Book Value | 5.35x |
Symbiotec Pharmalab IPO Peer Comparison
| Company | P/E | EPS | RoNW | NAV |
| Concord Biotech Limited | 61.07x | ₹24.78 | 14.00% | — |
| Divi’s Laboratories Limited | 87.80x | ₹96.75 | 16.50% | ₹631 |
| Cohance Lifesciences | 95.02x | ₹4.69 | 7.00% | — |
| Laurus Labs Limited | 109.36x | ₹16.47 | 16.80% | — |
Symbiotec Pharmalab IPO Dates
| Open Date | August 24, 2026 |
| Close Date | August 27, 2026 |
| Allotment Date | August 28, 2026 |
| Refund Date | August 31, 2026 |
| Share Credit Date | August 31, 2026 |
| Listing Date | September 01, 2026 |
Symbiotec Pharmalab Limited Company Financial Report (Restated)
| Period Ended | Total Assets | Total Income | Total Expenses | Net Worth | Profit After Tax | EBITDA | Reserves and Surplus | Total Borrow |
|---|---|---|---|---|---|---|---|---|
| March 2026 | ₹1,780.79 Cr. | ₹872.26 Cr. | ₹709.90 Cr. | ₹1,158.64 Cr. | ₹109.90 Cr. | ₹231.97 Cr. | ₹1,145.95 Cr. | ₹387.91 Cr. |
| March 2025 | ₹1,579.65 Cr. | ₹755.98 Cr. | ₹688.85 Cr. | ₹821.15 Cr. | ₹96.79 Cr. | ₹206.11 Cr. | ₹810.03 Cr. | ₹540.92 Cr. |
| March 2024 | ₹1,294.79 Cr. | ₹723.33 Cr. | ₹590.99 Cr. | ₹720.68 Cr. | ₹100.06 Cr. | ₹177.04 Cr. | ₹709.54 Cr. | ₹247.21 Cr. |
Company Promoters
- Anil Satwani
- Kashish Satwani
- Sushil Satwani
- Satwani Holdings LLP
| Holding Pre Issue | 6,16,81,496 Shares | 34.47% |
| Holding Post Issue | 6,32,02,757 Shares | — |
Symbiotec Pharmalab IPO Lead Managers
- JM Financial Limited
- Avendus Capital Private Limited
- Motilal Oswal Investment Advisors Limited
- Nomura Financial Advisory & Securities (India) Private Limited
Symbiotec Pharmalab IPO Registrar
MUFG Intime India Privare Limited
Telephone: 022-49186000
Email: symbiotecpharmalab.ipo@in.mpms.mufg.com
Website: https://in.mpms.mufg.com/Initial_Offer/public-issues.html
About Symbiotec Pharmalab Limited (Incorporated In 2002)
It is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms – organic chemistry, biotechnology, and complex injectables. It holds a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients (“APIs”) by volume in fiscal 2026, with a global volume market share of 38.2% in corticosteroids and 23.8% in steroidal-hormone APIs (excluding androstenedione and hydroxyprogesterone caproate). (Source: F&S Report)
It is the only Indian and global company to be present in the top 10 corticosteroid and steroidal-hormone APIs in fiscal 2026, demonstrating the depth of its portfolio. (Source: F&S Report) It manufactures these products using fermentation and multi-step complex chemical reactions. With over 30 years of industry experience, we have transformed from a lab-scale steroidal-hormone API manufacturer in 1995 to an industrial-scale, backward-integrated platform approved by the United States Food and Drug Administration (“US FDA”), European Union Good Manufacturing Practices (“EU-GMP”), Ministry of Food and Drug Safety, Korea, and other global organizations.
Leveraging our deep capabilities in organic chemistry, biotechnology, and complex injectables, we have served as a contract development and manufacturing organization (“CDMO”) for specialty pharmaceutical and nutraceutical companies worldwide, offering products and services across all three platforms, including our own products. As of March 31, 2026, we had two operational industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tons (“MT“) and a fermentation capacity of 300 kiloliters (“KL“).
Additionally, we have commissioned two additional manufacturing facilities in Ujjain, Madhya Pradesh and Mhow, Madhya Pradesh, bringing the total maximum chemical synthesis capacity to 584.67 MT, maximum fermentation capacity to 700 KL, and complex injectables capacity to 20 million vials per annum, enabling us to operate as a vertically integrated ‘microbe-to-pharmacy’ and ‘farm-to-pharmacy’ platform with cost-efficient operations.
Their biotechnology facilities are equipped with 5 KL, 35 KL, and 100 KL fermenters, providing flexibility in the scale of their operations. Additionally, they are in the process of expanding their biologics capacity by adding a proposed dedicated 14 KL (comprising two 7 KL reactors) fermentation capacity for biologics manufacturing in Ujjain, Madhya Pradesh.
Company Strengths (In Details)
- Global leadership in corticosteroid and steroidal hormone APIs
- Long-standing relationships with domestic and global customer base
- Fully-invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and clean regulatory track record
- Continuous investment in R&D, with leading technological capabilities among Indian peers
- Ability to leverage science and existing competencies to increase total addressable market and deepen intellectual property-driven offerings.
Objects Of The Issue (Total Estimated Amount ₹112.50 Cr.)
- Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company. (Estimated ₹112.50 Cr.)
- General corporate purposes.
Company Address
Symbiotec Pharmalab Limited
Address: 385/2, Pigdamber, Rau, Mhow,
Indore, Madhya Pradesh, 453331
Telephone: +91 731 667 6405
Email: secretarial@symbiotec.com
Website: https://www.symbiotec.com/
Symbiotec Pharmalab IPO FAQs
What are the open and close dates of the Symbiotec Pharmalab IPO?
The Symbiotec Pharmalab IPO will open on August 24, 2026 and close on August 27, 2026.
What is the price band for Symbiotec Pharmalab IPO?
The price band for the Symbiotec Pharmalab IPO is ₹938 to ₹988 per share.
What is the issue size of the Symbiotec Pharmalab IPO?
The total issue size of the Symbiotec Pharmalab IPO is ₹1,757.00 Cr., comprising both fresh issue and offer for sale (if applicable).
What is Symbiotec Pharmalab IPO Minimum and Maximum Lot Size?
The minimum bid is 1 Lot, 15 Shares with ₹14,820 amount while the maximum bid is 13 Lot, 195 shares with ₹1,92,660 for the Symbiotec Pharmalab IPO.
What is Symbiotec Pharmalab IPO Investors Portion?
The investors portion for QIB 50%, NII 15%, RII 35% for the Symbiotec Pharmalab IPO.
When will the allotment for the Symbiotec Pharmalab IPO be finalized?
The Symbiotec Pharmalab IPO allotment is expected to be finalized on August 28, 2026.
When will the shares of Symbiotec Pharmalab IPO get listed?
The Symbiotec Pharmalab IPO shares are expected to be listed on BSE and NSE on September 01, 2026.
| Read Also |
|---|
| Symbiotec Pharmalab IPO GMP |
| Symbiotec Pharmalab IPO Subscription Status |
| Symbiotec Pharmalab IPO Allotment Status |
Desclaimer: This Content Has Been Researched And Prepared By The IPO Investors Team After Reviewing The Symbiotec Pharmalab IPO Red Herring Prospectus (RHP) And Other Official IPO-Related Documents Publicly Available To Investors. The Information Is Provided For Informational And Educational Purposes Only And Should Not Be Considered Investment advice.
| Thank You… |
|---|
Share the post "Symbiotec Pharmalab IPO Dates, Price, Issue Size & More Details 2026"